Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

证券代码：688799 证券简称：华纳药厂 公告编号：2025-062 湖南华纳大药厂股份有限公司 自愿披露关于子公司原料药获得上市申请批准通知 书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）全资子公司湖南 华纳大药厂手性药物有限公司（以下简称"手性药物"）收到国家药品监督管理 局签发的硫酸镁《化学原料药上市申请批准通知书》（通知书编号：2025YS00481）， 并在国家药品监督管理局药品审评中心（CDE）"原辅包登记信息"平台公示。 具体情况如下： 一、原料药登记信息 1、化学原料药名称：硫酸镁 6、生产地址：湖南省长沙市望城区铜官循环经济工业基地铜官大道 139 号 7、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品审批的有关规定，批准生产本品。质量标准、标签及生产工艺照所 附执行。 8、与制剂共同审评审批结果：A 二、药品的相关情况 硫酸镁是硫酸镁钠钾口服用浓溶液和硫酸镁注射液的原料药之一。硫酸镁钠 钾口服用浓溶液适用于成 ...

湖南华纳大药厂股份有限公司 2025 年第一次临时股东大会会议材料 证券代码：688799 证券简称：华纳药厂 湖南华纳大药厂股份有限公司 湖南华纳大药厂股份有限公司 2025 年第一次临时股东大会 会议材料 六、本次大会现场会议于 2025 年 6 月 27 日下午 14：30 正式开始，如股东（或股东代 表）欲在本次股东大会上发言，可在签到时先向大会会务组登记。会上主持人将统筹安排股 东（或股东代表）发言。股东（或股东代表）的发言主题应与本次会议议题相关。发言或提 问时需说明股东名称及所持股份总数，发言或提问请简明扼要，时间不超过 5 分钟。每位股 东及股东代理人发言或提问次数不超过 2 次。股东及股东代理人要求发言或提问时，不得打 断会议报告人的报告或其他股东及股东代理人的发言。在股东大会进行表决时，股东及股东 代理人不再进行发言。股东及股东代理人违反上述规定，会议主持人有权加以拒绝或制止。 主持人可安排公司董事、监事或高级管理人员以及候选人等回答股东所提问题。对于可能将 泄露公司商业秘密及/或内幕信息，损害公司、股东共同利益的提问，主持人或其指定人员 有权拒绝回答。 七、为提高股东大会议事效率，在就股 ...

湖南华纳大药厂股份有限公司 2025 年第一次临时股东大会会议材料 湖南华纳大药厂股份有限公司 2025 年第一次临时股东大会会议材料 2025 年 6 月 | | | 证券代码：688799 证券简称：华纳药厂 | 2025 年第一次临时股东大会会议材料 1 | | | --- | --- | | 会议须知 | 1 | | 会议议程 | 3 | | 一、会议召开基本情况 3 | | | 二、会议议程 | 3 | | 议案一：关于部分募集资金投资项目子项目调整及延期的方案的议案 5 | | 湖南华纳大药厂股份有限公司 2025 年第一次临时股东大会会议材料 会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的顺利 进行，根据《中华人民共和国公司法》（以下简称"公司法"）、《湖南华纳大药厂股份有 限公司章程》（以下简称"公司章程"）、《湖南华纳大药厂股份有限公司股东大会议事规 则》（以下简称"议事规则"）及中国证监会、上交所有关规定，特制定本须知： 一、本公司根据《公司法》、《公司章程》、《议事规则》等有关规定，认真做好召开 股东大会的各项工作。 二、本次大会期间，全体参会人员应以 ...

Group 1 - The first "doubling fund" in the public fund market for 2025 is the Huatai-PineBridge Hong Kong Advantage Selection A, which has achieved a 99.5% year-to-date return as of June 13, 2025, leading the entire market [1][2] - Among the top 10 funds for year-to-date returns in 2025, 8 are heavily invested in pharmaceutical companies, particularly in the innovative drug sector [1][2] - The innovative drug sector has seen significant growth, with the Wind Innovative Drug Concept Index rising over 25% and the Hang Seng Innovative Drug Index increasing over 53% since April 9, 2025 [2][3] Group 2 - Notable stocks in the innovative drug sector have experienced substantial price increases, with Shuyou Pharmaceutical leading at a 478.84% increase, followed by Sanofi Health at 129.81% [3][4] - The top-performing funds have a high concentration of investments in innovative drug companies, with the most frequently held stock being Kelong Biotechnology-B, which has also doubled in price [4][5] - Fund managers of the top-performing funds are predominantly new faces, with half of them having less than two years of investment experience [5][6] Group 3 - Zhang Wei, the manager of Huatai-PineBridge Hong Kong Advantage Selection A, has maintained a strong focus on the pharmaceutical sector, with the fund's top holdings consistently being in the biopharmaceutical industry [7][8] - The fund has shown resilience despite previous years of losses, with a significant recovery in 2025 attributed to the performance of its long-held innovative drug stocks [9][10] - Zhang Wei's investment strategy emphasizes long-term perspectives and stability in holdings, focusing on companies with global competitiveness and growth potential in the pharmaceutical and biotech sectors [10][11] Group 4 - The performance disparity among active equity funds in 2025 is notable, with 12 funds experiencing declines of over 20%, including several managed by Jin Zicai [13][14] - Jin Zicai's aggressive investment style has led to high turnover rates and concentrated positions, which can result in significant volatility [15][16] - The overall market sentiment towards innovative drugs remains positive, with expectations for continued growth driven by domestic medical demand recovery and supportive policies [10][11]

Summary of Key Points Core Viewpoint - The company, Hunan Warner Pharmaceutical Co., Ltd., is adjusting and postponing certain fundraising investment projects to enhance the efficiency of fund utilization and align with market conditions and internal project progress [1][18]. Fundraising Investment Project Overview - The company raised a total of RMB 723.27 million by issuing 23.5 million shares at RMB 30.82 per share, with a net amount of RMB 655.65 million after deducting related fees [1][2]. - The funds are stored in a special account, and a tripartite supervision agreement has been signed among the company, the sponsor, and the bank [2]. Fund Usage Status - As of May 31, 2025, the cumulative investment in the high-end raw material drug production base construction project (Phase I) is RMB 414.01 million, with a total investment of RMB 655.65 million [3][4]. - The company has completed the Phase I project and transferred surplus funds to supplement working capital [3][5]. Adjustments and Postponements - The company has decided to reduce the funding for the traditional Chinese medicine preparation and quality testing center project from RMB 94.28 million to RMB 29.28 million and extend the project duration from two to three years [5][13]. - Surplus funds from completed projects will be redirected to ongoing and new projects, optimizing the allocation of resources [13][18]. R&D Focus and Future Plans - The company aims to enhance its product pipeline in various therapeutic areas, including respiratory, analgesic, cardiovascular, and neurological systems, with a focus on innovative drug development [10][11]. - Specific funding allocations include RMB 47.6 million for respiratory products and RMB 47.8 million for analgesic products [10][11]. Feasibility Analysis - The company has established core technology platforms and a strong R&D team to support ongoing projects, ensuring the capability to meet future development needs [17][18]. - The adjustments made are in line with the company's strategic planning and operational requirements, aiming to capture market opportunities without adversely affecting normal operations [18][19].

国投证券股份有限公司 关于湖南华纳大药厂股份有限公司 部分募集资金投资项目子项目调整 及延期的专项核查意见 国投证券股份有限公司（以下简称"国投证券"或"保荐机构"）作为湖南 华纳大药厂股份有限公司（以下简称"华纳药厂"或"公司"）向不特定对象发 行可转换公司债券的保荐机构，根据《证券发行上市保荐业务管理办法》《上市 公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求（2022 年修订）》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证 券交易所科创板股票上市规则》《湖南华纳大药厂股份有限公司募集资金管理制 度》等有关规定，对公司部分募集资金投资项目子项目调整及延期进行了认真、 审慎的核查，并发表意见如下： 一、募集资金投资项目概况 （一）募集资金基本情况 根据中国证券监督管理委员会《关于同意湖南华纳大药厂股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕1966 号），公司由主承销商西部证 券股份有限公司采用余额包销方式，向社会公众公开发行人民币普通股（A 股） 股票 2,350 万股，发行价为每股人民币 30.82 元，共计募集资金 72,427.00 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-061 湖南华纳大药厂股份有限公司 关于部分募集资金投资项目子项目调整及延期的公 告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南华纳大药厂股份有限公司（以下简称"公司"）于 2025 年 6 月 12 日在 上海证券交易所网站（www.sse.com.cn）披露了《湖南华纳大药厂股份有限公司 关于部分募集资金投资项目子项目调整及延期的公告》（公告编号：2025-059）， 经核查发现，上述公告中有关公司募集资金使用情况的内容有误，现对上述内容 更正如下： 更正前： 截至 2025 年 5 月 31 日，公司募集资金使用计划及使用情况如下： 单位：万元 募集资金计 募集资金累 序号 项目名称 项目状态 划投入金额 计投入金额 合计 65,565.48 40,836.01 更正后： 截至 2025 年 5 月 31 日，公司募集资金使用计划及使用情况如下： 单位：万元 序号 项目名称 募集资金计 募集资金累 项目状态 划投入金额 计投入金额 合 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南华纳大药厂股份有限公司（以下简称"公司"）于 2025 年 6 月 12 日在 上海证券交易所网站（www.sse.com.cn）披露了《湖南华纳大药厂股份有限公司 关于部分募集资金投资项目子项目调整及延期的公告》（公告编号：2025-059）， 经核查发现，上述公告中有关公司募集资金使用情况的内容有误，现对上述内容 更正如下： 更正前： 截至 2025 年 5 月 31 日，公司募集资金使用计划及使用情况如下： 证券代码：688799 证券简称：华纳药厂 公告编号：2025-061 湖南华纳大药厂股份有限公司 关于部分募集资金投资项目子项目调整及延期的公 告的更正公告 单位：万元 序号 项目名称 募集资金计 募集资金累 项目状态 | | | | 划投入金额 | 计投入金额 | | | --- | --- | --- | --- | --- | --- | | 1 | 年产 1000 | 吨高端原料药物生产基地建设项目（一期）续建 | 2,900.06 | 2,656.2 ...

Core Viewpoint - The company plans to adjust and postpone certain sub-projects within its fundraising investment project for drug research and development, while maintaining the total investment amount for the "Drug Research and Development Project" unchanged [1][2][3] Fundraising Investment Project Overview - The company raised a total of RMB 724.27 million by issuing 23.5 million shares at RMB 30.82 per share, with a net amount of RMB 655.65 million after deducting related expenses [1][2] - As of May 31, 2025, the cumulative investment from the raised funds amounted to RMB 408.36 million [2] Adjustments and Postponements - The adjustments involve reallocating unspent funds from completed projects to ongoing or new projects, optimizing the priority of funding based on market conditions and research progress [4][5] - The company aims to enhance the efficiency of fund usage while ensuring that the total investment in the "Drug Research and Development Project" remains unchanged [3][4] Specific Adjustments - Funds from completed projects such as "Compound Polyethylene Glycol Electrolyte Powder" and others will be redirected to ongoing projects like "Qianqing Granules" and new investment projects [5][6] - The company will extend the research timelines for projects like "Qianqing Granules" and "L-Carnitine Oral Solution" to the end of 2028, adjusting funding allocations accordingly [6][8] Research and Development Focus - The company continues to focus on projects in the digestive, respiratory, and anti-infection fields, while also expanding into pain relief, cardiovascular, neurological, and lymphatic treatment areas [8][9] - A total of RMB 47.6 million is allocated for respiratory products, and RMB 47.8 million for pain relief products, among other therapeutic areas [9][10][12] Feasibility Analysis - The company's drug research capabilities and a strong core research team support the ongoing implementation of projects, ensuring a robust pipeline for future product development [15][16] - The adjustments are made to align with market demands and the company's strategic planning, without negatively impacting normal operations or shareholder interests [17][18]